6 registrations that name soy isoflavones as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
All 6 registrations
RecruitingNCT06689566
Evaluating Metabolic and Anti-inflammatory Effect of Genistein on Post-myocardial Infarction Patients
No phase
National Taiwan University Hospital
About 73 people
Starts Sep 2025 (estimated)
In plain words A study of soy isoflavones in people 18 and older, run by National Taiwan University Hospital. It plans to enroll about 73 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Myocardial Infarction (MI).
Written informed consent.
Age ≥ 18 years.
History of spontaneous myocardial infarction at least 28 days before recruitment.
hsCRP ≥ 0.1 mg/dL
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
genistein
Registered summary
The goal of this clinical trial is to learn if genistein works to provide a beneficial effect to show lipid lowering effect and anti-inflammatory effects and slow the progression of atherosclerosis in post-myocardial infarction adults. It will also learn about the safety of genistein. The main questions it aims to answer are: Does genistein lower triglyceride in participants? What medical problems do participants have when taking genistein? Researchers will compare the baseline, under treatment and washout period triglyceride, hsCRP to see if genistein works to decrease inflammation. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT06634108
Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy
Phase 1 and 2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
About 20 people
Started Sep 27, 2024
In plain words A Phase 1 and 2 study of soy isoflavones in people 40 to 80, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. It plans to enroll about 20 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 80. Conditions: Amyloid Cardiomyopathy.
Age: 40-80 years
Heart failure with Reduced Ejection Fraction
ischemic or nonischemic etiology
LVEF <40% by echocardiography, MUGA, or MRI
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Genistein
Registered summary
This Phase 1b/2a study aims to investigate the safety and efficacy of genistein in patients with Transthyretin (TTR) Amyloidosis. The focus is on its impact on inflammatory and cardiometabolic biomarkers, along with the effects on cardiac function and exercise capacity. Blood samples will be collected at baseline, following each dose of genistein, and after a six-week placebo washout period. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT07385937
Effectiveness of Genistein in Mild Cognitive Impairment
No phase
Universidad Católica San Antonio de Murcia
About 150 people
Starts Feb 2026 (estimated)
In plain words A study of soy isoflavones in people 50 and older, run by Universidad Católica San Antonio de Murcia. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older. Conditions: Alzheimer Disease (AD); Mild Cognitive Impairment (MCI).
Patient over 50 years of age.
Patient diagnosed with mild cognitive impairment (MCI) for Alzheimer's disease (AD) according to the National Institute on Aging and Alzheimer's Association (NIA-AA, 2024) criteria:
MMSE scores between 22 and 30 (inclusive; exceptions may be made for subjects with less than 5 years of education).
Evidence of concern about change in cognition, compared to the person's previous level (subjective memory complaint/impairment for more than 6 months in the past year and/or confirmed by the informant and/or physician).
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Genistein; Control product placebo
Registered summary
Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in patients with prodromal Alzheimer's disease.
Where, as registered
No US site; Spain (1).
Not yet recruitingNCT07785388
Genistein for the Reduction of Adverse Cardiovascular Events (GRACE)
Phase 1 and 2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
About 60 people
Starts Sep 30, 2026 (estimated)
In plain words A Phase 1 and 2 study of soy isoflavones in people 18 to 80, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: HIV; Vascular Disease; Inflammation; Pain Management.
age: 19-80
males and females
all ethnicities
no history of cardiovascular disease
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Genistein (Unconjugated Isoflavones 100); Placebo
Registered summary
People living with HIV (PLHIV) live longer because of modern HIV medicines, but even with these treatments, their bodies are more inflamed. Long term inflammation increases the risk of heart disease, chronic pain, lung disease, dementia, arthritis, and other infections. Because some anti-inflammatory medicines can cause serious side effects, interact with HIV drugs, or be costly, safer and more affordable treatment options are needed. Genistein is a natural compound found in soy foods. It is considered safe and has been shown to reduce inflammation and improve blood vessel health. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT07623044
Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD
Phase 2
Eastern Hepatobiliary Surgery Hospital
About 44 people
Starts May 21, 2026 (estimated)
In plain words A Phase 2 study of soy isoflavones in people 18 to 70, run by Eastern Hepatobiliary Surgery Hospital. It plans to enroll about 44 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease.
Adults aged 18 to 70 years.
Male or female participants.
Scheduled to undergo elective laparoscopic cholecystectomy or other benign biliary surgery for benign biliary disease.
Diagnosis of metabolic dysfunction-associated steatotic liver disease based on hepatic steatosis shown by liver biopsy or imaging, including controlled attenuation parameter, ultrasound, or magnetic resonance imaging, together with at…
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Daidzein
Registered summary
This clinical trial aims to learn whether daidzein can improve liver tissue changes in adults with metabolic dysfunction-associated steatotic liver disease, also called MASLD. MASLD is a liver condition linked to extra fat in the liver and metabolic problems such as obesity, diabetes, abnormal blood lipids, or high blood pressure. Daidzein is a natural compound found in soy. Earlier laboratory studies suggest that daidzein may help protect the liver. This study will test whether taking daidzein for a short time before surgery can improve liver tissue findings in people with MASLD. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07033767
Exploring a Natural Solution for Childhood Obesity
Phase 1 and 2
Western University
About 30 people
Starts Aug 1, 2025 (estimated)
In plain words A Phase 1 and 2 study of soy isoflavones in people 4 to 17, run by Western University. It plans to enroll about 30 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 17. Conditions: Obesity; Children.
Children and adolescents aged 4-17 years.
Obesity defined as a BMI z-score ≥ 2 for age and sex, based on World Health Organization (WHO) reference standards.
Stable or increasing BMI after at least 3 months of enrollment in the HEAL program.
Inclusion of participants from all backgrounds, consistent with principles of equity, diversity, and inclusion.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
genistein
Registered summary
This study aims to assess the safety tolerability, adherence and effectiveness of genistein as an anti-obesity treatment for children and adolescents. The primary goal is determining how well genistein is tolerated and adhered to by pediatric patients with obesity. Secondary goals include evaluating its impact on body mass index z-scores and cardiometabolic risk factors, such as inflammation. Participants aged 4-18 will be recruited from the Paediatric HEAL (Healthy Eating, Activity \& Lifestyle) Program at the Children's Hospital - London Health Science Center in London, Ontario. The full summary is on the listing.